Phase II study of recombinant beta inter
โ
Ettinger, David S. ;Harwood, Kerry
๐
Article
๐
1988
๐
John Wiley and Sons
๐
English
โ 238 KB
Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever a